Maynard Um
-
-
-
-
-
-
-
Cellectar Biosciences data accepted for ASCO 2026 presentation
-
-
-
-
-
-
-
Cellectar gets EMA eligibility for conditional approval of cancer drug
-
-
-
-
-
-
-
Cellectar Biosciences (CLRB) stock soars on FDA breakthrough designation
-
-
-
-
-
-
-
Cellectar Biosciences (CLRB) PT Lowered to $12 at Oppenheimer
-
-
-
-
-
444,478 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

